Metastatic Hepatocellular Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major metastatic hepatocellular carcinoma markets are expected to exhibit a CAGR of 13.63% during 2024-2034.
The metastatic hepatocellular carcinoma market has been comprehensively analyzed in IMARC's new report titled "Metastatic Hepatocellular Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic hepatocellular carcinoma (HCC) is an advanced stage of liver cancer characterized by the spread of malignant cells from the liver to various other parts of the body. It primarily originates in the liver's hepatocytes, and its metastatic form indicates a more aggressive and challenging disease state. The symptoms of the ailment can vary, often including abdominal pain, unexplained weight loss, fatigue, jaundice (yellowing of the eyes and skin), and stomach swelling due to fluid accumulation. These indications are frequently non-specific and may overlap with numerous other health conditions, making an accurate diagnosis crucial. The diagnosis of metastatic HCC involves a combination of medical history assessment, physical examination, and imaging techniques like computed tomography scans, magnetic resonance imaging, and positron emission tomography scans. Additionally, blood tests are performed to measure the levels of alpha-fetoprotein (AFP) and several other markers associated with liver function that can aid in diagnosis and monitoring.
The escalating cases of various risk factors, like chronic alcohol consumption, exposure to aflatoxins, obesity, diabetes, genetic predisposition, etc., are primarily driving the metastatic hepatocellular carcinoma market. In addition to this, the inflating utilization of advanced therapeutic agents, including tyrosine kinase inhibitors, immune checkpoint inhibitors, and multi-kinase inhibitors, aimed at effectively managing disease progression and curtailing further deterioration, is creating a positive outlook for the market. Moreover, the widespread adoption of minimally invasive procedures and surgical interventions, such as radiofrequency ablation, transarterial chemoembolization, and liver transplantation, is also bolstering the market growth. These interventions play a pivotal role in arresting the malignancy's advancement and improving the quality of life for individuals suffering from the illness. Apart from this, the rising usage of palliative care strategies, since they are designed to alleviate symptoms, enhance patient comfort, and provide comprehensive support, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of novel diagnostic techniques, like liquid biopsy, which detects cancer-related genetic material circulating in the bloodstream, thereby aiding in early detection and monitoring of disease progression, is also augmenting the market growth. Furthermore, the increasing application of personalized immunotherapy, an innovative approach that harnesses the patient's immune system to selectively target and eliminate cancer cells, is expected to drive the metastatic hepatocellular carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the metastatic hepatocellular carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic hepatocellular carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic hepatocellular carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the metastatic hepatocellular carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the metastatic hepatocellular carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current metastatic hepatocellular carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the metastatic hepatocellular carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the metastatic hepatocellular carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the metastatic hepatocellular carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of metastatic hepatocellular carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic hepatocellular carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic hepatocellular carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with metastatic hepatocellular carcinoma across the seven major markets?
What is the size of the metastatic hepatocellular carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of metastatic hepatocellular carcinoma?
What will be the growth rate of patients across the seven major markets?
Metastatic Hepatocellular Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for metastatic hepatocellular carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic hepatocellular carcinoma market?
What are the key regulatory events related to the metastatic hepatocellular carcinoma market?
What is the structure of clinical trial landscape by status related to the metastatic hepatocellular carcinoma market?
What is the structure of clinical trial landscape by phase related to the metastatic hepatocellular carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the metastatic hepatocellular carcinoma market?
The metastatic hepatocellular carcinoma market has been comprehensively analyzed in IMARC's new report titled "Metastatic Hepatocellular Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic hepatocellular carcinoma (HCC) is an advanced stage of liver cancer characterized by the spread of malignant cells from the liver to various other parts of the body. It primarily originates in the liver's hepatocytes, and its metastatic form indicates a more aggressive and challenging disease state. The symptoms of the ailment can vary, often including abdominal pain, unexplained weight loss, fatigue, jaundice (yellowing of the eyes and skin), and stomach swelling due to fluid accumulation. These indications are frequently non-specific and may overlap with numerous other health conditions, making an accurate diagnosis crucial. The diagnosis of metastatic HCC involves a combination of medical history assessment, physical examination, and imaging techniques like computed tomography scans, magnetic resonance imaging, and positron emission tomography scans. Additionally, blood tests are performed to measure the levels of alpha-fetoprotein (AFP) and several other markers associated with liver function that can aid in diagnosis and monitoring.
The escalating cases of various risk factors, like chronic alcohol consumption, exposure to aflatoxins, obesity, diabetes, genetic predisposition, etc., are primarily driving the metastatic hepatocellular carcinoma market. In addition to this, the inflating utilization of advanced therapeutic agents, including tyrosine kinase inhibitors, immune checkpoint inhibitors, and multi-kinase inhibitors, aimed at effectively managing disease progression and curtailing further deterioration, is creating a positive outlook for the market. Moreover, the widespread adoption of minimally invasive procedures and surgical interventions, such as radiofrequency ablation, transarterial chemoembolization, and liver transplantation, is also bolstering the market growth. These interventions play a pivotal role in arresting the malignancy's advancement and improving the quality of life for individuals suffering from the illness. Apart from this, the rising usage of palliative care strategies, since they are designed to alleviate symptoms, enhance patient comfort, and provide comprehensive support, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of novel diagnostic techniques, like liquid biopsy, which detects cancer-related genetic material circulating in the bloodstream, thereby aiding in early detection and monitoring of disease progression, is also augmenting the market growth. Furthermore, the increasing application of personalized immunotherapy, an innovative approach that harnesses the patient's immune system to selectively target and eliminate cancer cells, is expected to drive the metastatic hepatocellular carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the metastatic hepatocellular carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic hepatocellular carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic hepatocellular carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the metastatic hepatocellular carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the metastatic hepatocellular carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current metastatic hepatocellular carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the metastatic hepatocellular carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the metastatic hepatocellular carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the metastatic hepatocellular carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of metastatic hepatocellular carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic hepatocellular carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic hepatocellular carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with metastatic hepatocellular carcinoma across the seven major markets?
What is the size of the metastatic hepatocellular carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of metastatic hepatocellular carcinoma?
What will be the growth rate of patients across the seven major markets?
Metastatic Hepatocellular Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for metastatic hepatocellular carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic hepatocellular carcinoma market?
What are the key regulatory events related to the metastatic hepatocellular carcinoma market?
What is the structure of clinical trial landscape by status related to the metastatic hepatocellular carcinoma market?
What is the structure of clinical trial landscape by phase related to the metastatic hepatocellular carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the metastatic hepatocellular carcinoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 METASTATIC HEPATOCELLULAR CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 METASTATIC HEPATOCELLULAR CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 METASTATIC HEPATOCELLULAR CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 METASTATIC HEPATOCELLULAR CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 METASTATIC HEPATOCELLULAR CARCINOMA - UNMET NEEDS
10 METASTATIC HEPATOCELLULAR CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 METASTATIC HEPATOCELLULAR CARCINOMA - MARKETED PRODUCTS
11.1 List of Metastatic Hepatocellular Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 METASTATIC HEPATOCELLULAR CARCINOMA - PIPELINE DRUGS
12.1 List of Metastatic Hepatocellular Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 TTI-101- Tvardi Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MIV-818 - Medivir
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. METASTATIC HEPATOCELLULAR CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. METASTATIC HEPATOCELLULAR CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 METASTATIC HEPATOCELLULAR CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Metastatic Hepatocellular Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Metastatic Hepatocellular Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Metastatic Hepatocellular Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Metastatic Hepatocellular Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Metastatic Hepatocellular Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Metastatic Hepatocellular Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Metastatic Hepatocellular Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Metastatic Hepatocellular Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
16 METASTATIC HEPATOCELLULAR CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 METASTATIC HEPATOCELLULAR CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 METASTATIC HEPATOCELLULAR CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 METASTATIC HEPATOCELLULAR CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 METASTATIC HEPATOCELLULAR CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 METASTATIC HEPATOCELLULAR CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 METASTATIC HEPATOCELLULAR CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 METASTATIC HEPATOCELLULAR CARCINOMA - UNMET NEEDS
10 METASTATIC HEPATOCELLULAR CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 METASTATIC HEPATOCELLULAR CARCINOMA - MARKETED PRODUCTS
11.1 List of Metastatic Hepatocellular Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 METASTATIC HEPATOCELLULAR CARCINOMA - PIPELINE DRUGS
12.1 List of Metastatic Hepatocellular Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 TTI-101- Tvardi Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MIV-818 - Medivir
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. METASTATIC HEPATOCELLULAR CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. METASTATIC HEPATOCELLULAR CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 METASTATIC HEPATOCELLULAR CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Metastatic Hepatocellular Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Metastatic Hepatocellular Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Metastatic Hepatocellular Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Metastatic Hepatocellular Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Metastatic Hepatocellular Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Metastatic Hepatocellular Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Metastatic Hepatocellular Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Metastatic Hepatocellular Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Metastatic Hepatocellular Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Metastatic Hepatocellular Carcinoma - Access and Reimbursement Overview
16 METASTATIC HEPATOCELLULAR CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 METASTATIC HEPATOCELLULAR CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 METASTATIC HEPATOCELLULAR CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
